Latest Insider Transactions at Chinook Therapeutics, Inc. (KDNY)
This section provides a real-time view of insider transactions for Chinook Therapeutics, Inc. (KDNY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CHINOOK THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CHINOOK THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 11
2023
|
Andrew James King Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,157
-100.0%
|
-
|
|
Aug 11
2023
|
Mahesh Krishnan Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,275
-100.0%
|
-
|
|
Aug 11
2023
|
Dolca Thomas Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,300
-100.0%
|
-
|
|
Aug 11
2023
|
Eric Bjerkholt Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
39,371
-100.0%
|
-
|
|
Aug 11
2023
|
Davis Jerel Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,035,207
-100.0%
|
-
|
|
Aug 11
2023
|
Davis Jerel Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
447,013
-100.0%
|
-
|
|
Aug 11
2023
|
Eric Dobmeier President, CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
301,138
-100.0%
|
-
|
|
Aug 11
2023
|
Tom Frohlich Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,777
-100.0%
|
-
|
|
Aug 11
2023
|
William Mariner Greenman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,643
-100.0%
|
-
|
|
Aug 11
2023
|
Michelle Renee Griffin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,300
-100.0%
|
-
|
|
Aug 11
2023
|
Srinivas Akkaraju Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,161,888
-100.0%
|
-
|
|
Aug 11
2023
|
Srinivas Akkaraju Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,300
-100.0%
|
-
|
|
Aug 01
2023
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,168
-5.75%
|
$45,552
$39.03 P/Share
|
|
Jul 29
2023
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+14.09%
|
-
|
|
May 30
2023
|
William Mariner Greenman Director |
SELL
Open market or private sale
|
Direct |
1,155
-4.66%
|
$26,565
$23.3 P/Share
|
|
May 26
2023
|
Ross Haghighat Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+2.58%
|
-
|
|
May 26
2023
|
Srinivas Akkaraju Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+50.0%
|
-
|
|
May 26
2023
|
William Mariner Greenman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+11.74%
|
-
|
|
May 26
2023
|
Dolca Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+19.88%
|
-
|
|
May 26
2023
|
Davis Jerel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+0.45%
|
-
|
|
May 26
2023
|
Michelle Renee Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+50.0%
|
-
|
|
Apr 24
2023
|
Eric Dobmeier President, CEO |
BUY
Open market or private sale
|
Direct |
1,200
+0.4%
|
$26,400
$22.26 P/Share
|
|
Apr 24
2023
|
Eric Dobmeier President, CEO |
SELL
Open market or private sale
|
Direct |
23,800
-7.3%
|
$499,800
$21.58 P/Share
|
|
Apr 24
2023
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.12%
|
$0
$0.42 P/Share
|
|
Apr 17
2023
|
Davis Jerel Director |
SELL
Open market or private sale
|
Direct |
295,808
-40.0%
|
$5,916,160
$20.75 P/Share
|
|
Apr 04
2023
|
Mahesh Krishnan Director |
SELL
Open market or private sale
|
Direct |
924
-42.02%
|
$21,252
$23.01 P/Share
|
|
Apr 03
2023
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-22.74%
|
$115,000
$23.34 P/Share
|
|
Apr 03
2023
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+10.21%
|
$0
$0.35 P/Share
|
|
Apr 01
2023
|
Mahesh Krishnan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,199
+50.0%
|
-
|
|
Mar 01
2023
|
Davis Jerel Director |
SELL
Open market or private sale
|
Indirect |
400,000
-13.23%
|
$8,800,000
$22.75 P/Share
|
|
Feb 10
2023
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,700
-2.4%
|
$85,100
$23.75 P/Share
|
|
Feb 10
2023
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,803
+4.22%
|
-
|
|
Feb 10
2023
|
Eric Dobmeier President, CEO |
SELL
Open market or private sale
|
Direct |
8,097
-2.62%
|
$186,231
$23.75 P/Share
|
|
Feb 10
2023
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,248
+6.15%
|
-
|
|
Feb 10
2023
|
Eric Bjerkholt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
857
-2.16%
|
$19,711
$23.75 P/Share
|
|
Feb 10
2023
|
Eric Bjerkholt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,435
+5.78%
|
-
|
|
Feb 10
2023
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,392
-10.93%
|
$55,016
$23.75 P/Share
|
|
Feb 10
2023
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,803
+23.71%
|
-
|
|
Jan 31
2023
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,566
-3.0%
|
$109,584
$24.68 P/Share
|
|
Jan 31
2023
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+5.19%
|
-
|
|
Jan 31
2023
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,244
-17.7%
|
$77,856
$24.68 P/Share
|
|
Jan 31
2023
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+31.26%
|
-
|
|
Jan 31
2023
|
Eric Bjerkholt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,891
-7.2%
|
$69,384
$24.68 P/Share
|
|
Jan 31
2023
|
Eric Bjerkholt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,333
+15.43%
|
-
|
|
Jan 31
2023
|
Eric Dobmeier President, CEO |
SELL
Open market or private sale
|
Direct |
7,688
-2.59%
|
$184,512
$24.68 P/Share
|
|
Jan 31
2023
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,999
+7.77%
|
-
|
|
Jan 30
2023
|
Eric Dobmeier President, CEO |
SELL
Open market or private sale
|
Direct |
25,000
-8.43%
|
$600,000
$24.54 P/Share
|
|
Jan 30
2023
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.77%
|
$0
$0.42 P/Share
|
|
Jan 03
2023
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-50.02%
|
$250,000
$25.82 P/Share
|
|
Jan 03
2023
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+27.28%
|
$0
$0.35 P/Share
|